~ Buy the LYTGOBI (futibatinib) Drug Profile, 2024 PDF Report in the Report Store ~

LYTGOBI Drug Patent Profile

When do Lytgobi patents expire, and when can generic versions of Lytgobi launch?

Lytgobi is a drug marketed by Taiho Oncology and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-nine patent family members in twenty-five countries.

The generic ingredient in LYTGOBI is futibatinib. One supplier is listed for this compound. Additional details are available on the futibatinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Lytgobi

Lytgobi will be eligible for patent challenges on September 30, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 30, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LYTGOBI

International Patents:	69
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	32
Patent Applications:	46
Drug Prices:	Drug price information for LYTGOBI
What excipients (inactive ingredients) are in LYTGOBI?	LYTGOBI excipients list
DailyMed Link:	LYTGOBI at DailyMed

See drug prices for LYTGOBI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LYTGOBI

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) GENE FUSIONS OR OTHER REARRANGEMENTS

NDA:

214801

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LYTGOBI

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Fibroblast Growth Factor Receptor Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for LYTGOBI

LYTGOBI is protected by three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) GENE FUSIONS OR OTHER REARRANGEMENTS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting LYTGOBI

FDA Regulatory Exclusivity protecting LYTGOBI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes			Y	Y
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes			Y
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes			Y	Y
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes

EU/EMA Drug Approvals for LYTGOBI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Taiho Pharma Netherlands B.V.	Lytgobi	futibatinib	EMEA/H/C/005627 Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Authorised	no	no	no	2023-07-04

International Patents for LYTGOBI

See the table below for patents covering LYTGOBI around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	S2300043
Brazil	112020018697	composição farmacêutica incluindo alquilsulfato de sódio
Singapore	2014009286	3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF
Taiwan	I508964
Mexico	351513	COMPUESTO DE ALQUINILBENCENO 3,5-DISUSTITUIDO Y SALES DEL MISMO. (3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF.)
European Patent Office	2657233	COMPOSÉ D'ALKYNYLBENZÈNE 3,5-DISUBSTITUÉ ET UN SEL DE CELUI-CI (3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF)
Mexico	2017012568	CRISTAL DEL COMPUESTO ALQUINIL BENCENO 3,5-DISUSTITUIDO. (CRYSTAL OF 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND.)

Supplementary Protection Certificates for LYTGOBI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2657233	301254	Netherlands		PRODUCT NAME: FUTIBATINIB OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1741 20230706
2657233	122023000066	Germany		PRODUCT NAME: FUTIBATINIB ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1741 20230704
2657233	CR 2023 00036	Denmark		PRODUCT NAME: FUTIBATINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/23/1741 20230706
2657233	2023C/548	Belgium		PRODUCT NAME: FUTIBATINIB OF EEN ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1741 20230706
2657233	CA 2023 00036	Denmark		PRODUCT NAME: FUTIBATINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/23/1741 20230706